Clinical Scorecard: Phase 1 Trial of ABBV-706, an Antibody-Drug Conjugate Targeting SEZ6, in Patients with Advanced Small Cell Lung Cancer and Other Solid Tumors

At a Glance

Key Highlights

• Overall Response Rate (ORR) observed in patients treated with ABBV-706.

• Preliminary safety profile indicates manageable adverse events.

• Potential for improved outcomes in relapsed/refractory SCLC patients.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of SCLC should be confirmed through histopathological examination.

• Imaging studies are recommended to assess disease extent.

Management

• Include specific chemotherapy regimens like platinum-etoposide.

• Consider ABBV-706 for patients with limited treatment options.

Monitoring & Follow-up

• Regular assessment of treatment response through imaging and clinical evaluation.

• Monitor for adverse effects and adjust treatment as necessary.

Risks

• Potential for infusion-related reactions.

• Risk of myelosuppression and other hematologic toxicities.

• Monitor for signs of neuropathy and other adverse effects related to treatment.

Patient & Prescribing Data

Adult patients with advanced solid tumors, specifically those with R/R SCLC.

ABBV-706 administered intravenously every three weeks, with a focus on safety and efficacy.

Clinical Best Practices

• Consider novel therapies like ABBV-706 for patients with limited treatment options.

• Monitor for safety and efficacy in patients receiving ABBV-706 monotherapy.

Related Resources & Content

1. The ASCO Post, HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors, 2025 -- HER3-Targeted Antibody-Drug Conjugate for Treatment-Resistant Solid Tumors

2. The ASCO Post, EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors, 2024 -- EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors

3. The ASCO Post, Clinical Trials Study the Role of Immunotherapy in the First-Line Setting of Non–Small Cell Lung Cancer, 2017 -- Clinical Trials Study the Role of Immunotherapy in the First-Line Setting of Non–Small Cell Lung Cancer

4. The ASCO Post, Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer, 2015 -- Antibody-Drug Conjugate Makes Strong Showing in Small Cell Lung Cancer

5. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide, Journal of Clinical Oncology -- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide

6. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer, FDA -- FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer

7. Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas, PubMed -- Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas

8. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) | Journal of Clinical Oncology

9. FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer | FDA

10. Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas - PubMed